HIGHLIGHTS
- who: Giorgia Colombo from the University of Bari Medical School, Italy have published the research: NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel disease, in the Journal: (JOURNAL)
- what: The authors replicated these findings on a larger cohort of patients treated with adalimumab and also evaluated eNAMPT and eNAPRT levels in a large cohort of IBD patients not on biological therapy. The authors show, for the first time, that both cytokines are elevated in faces of IBD patients, but their relative ratio compared to serum is different, with higher . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.